burden and an inability to comply with treatments, which leads to vision loss," Thomas
Chalberg, chief executive officer of Avalanche, said in an interview. "Our goal is to bring this ... study on the effectiveness of AVA-101 in the second half of this year, Chalberg said.
Wet AMD affects 150,000 people in the U.S., according to Avalanche. It typically
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01368453.pdf